Further research is needed to better understand the complexity of EZH2 and the relative contribution of its PRC2-dependent and independent roles in the abnormal phenotype of PAH-PASMCs, a prerequisite for developing the most relevant therapeutic approach. This evidence concerns the gene EZH2 and pulmonary arterial hypertension.